BNTCBenitec Biopharma Inc.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−26% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −26% vs its 200-day average.
Moderately shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How BNTC is trading
Benitec Biopharma Inc. is −46% over the past year while the S&P 500 is +16%: 62 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −26%
vs 200-day average · a clear downtrend
- RSI (14)
- 43
RSI (14) · neutral
- Below its 52-week high
- 48%
Below its 52-week high
Details›
- Last close2026-10-23
- $8.62
- 1 monthS&P 500 −0.94%
- −11%
- 1 yearS&P 500 +16%
- −46%
- 5 yearsS&P 500 +86%
- −86%
- vs 50-day average$10.82
- −20%
- 52-week high
- $16.52
- 52-week low
- $8.09
- Annualised volatility
- 63%
| Year | Return |
|---|---|
| 2026 (year to date) | −36% |
| 2025 | +6.7% |
| 2024 | +291% |
| 2023 | +12% |
| 2022 | −94% |
| 2021 | −13% |
| 2020 | −61% |
| 2019 | −66% |
| 2018 | −49% |
| 2017 | +93% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +4.8% |
| Feb | 10 | 6 of 10 | +16% |
| Mar | 10 | 7 of 10 | +3.8% |
| Apr | 10 | 5 of 10 | +5.3% |
| May | 10 | 4 of 10 | −5.2% |
| Jun | 10 | 3 of 10 | −10% |
| Jul | 11 | 5 of 11 | +4.5% |
| Aug | 11 | 5 of 11 | −0.07% |
| Sep | 11 | 3 of 11 | −10% |
| Oct | 11 | 7 of 11 | −3.7% |
| Nov | 10 | 3 of 10 | −5.7% |
| Dec | 10 | 6 of 10 | −2.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.